新戦略による貧血治療

出版社： 中山書店
著者：
発行日： 2014-07-15
分野： 臨床医学：内科  >  血液
ISBN： 9784521737799
電子書籍版： 2014-07-15 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

12,100 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

12,100 円(税込)

購入する

商品紹介

貧血は症候名であり，病態をはじめ診断法や治療法も異なる多種多様な疾患が含まれる．診療にあたっては原因疾患を明らかにして適切な治療を行わなくてはならない．本書では発症機序により，造血必須物質欠乏，溶血性，骨髄不全，続発性に大別して，病型ごとに，診断のポイント，標準療法，再発・難治例への対応などを詳述した．加えて，理解を深めるための関連項目をMini Lectureで取り上げた．

目次

  • 新戦略による貧血治療

    ―目次―

    序章
    　初診時のアプローチ

    第1章　造血必須物質の欠乏による貧血
    　鉄欠乏性貧血
    　〔Mini Lecture〕　鉄剤不応性/再発性鉄欠乏性貧血に対する
    　　　　　　　　　　　Helicobacter pylori除菌療法
    　〔Mini Lecture〕　鉄代謝のバイオマーカー　
    　巨赤芽球性貧血　
    　微量元素(亜鉛/銅)欠乏による貧血　
    　腎性貧血　
    　〔Mini Lecture〕　貧血患者に対する栄養指導　

    第2章　溶血性貧血
    　病型診断の進め方
    　自己免疫性溶血性貧血（温式）
    　〔Pitfall〕　Coombs陰性自己免疫性溶血性貧血
    　寒冷凝集素症
    　発作性寒冷ヘモグロビン尿症
    　発作性夜間ヘモグロビン尿症
    　遺伝性球状赤血球症
    　赤血球酵素異常症
    　サラセミア
    　不安定ヘモグロビン症

    第3章　骨髄不全とその周辺疾患
    　検査・診断
    　　免疫病態の診断
    　　異形成所見
    　　骨髄病理
    　　染色体分析・遺伝子検査
    　　フローイトメトリ―を用いた表面形質の解析
    　　画像検　査
    　　骨髄異形成症候群の病型分類
    　再生不良性貧血 <成人>
    　〔Mini Lecture〕　ATG投与後のEBV再活性化とその対策　
    　再生不良性貧血 <小児>　
    　Fanconi貧血　
    　〔Pitfall〕　成人Fanconi貧血−小児科医からのアドバイス　
    　先天性角化不全症
    　骨髄異形成症候群 <成人>　
    　〔Mini Lecture〕　5q−症候群
    　〔Pitfall〕　ICUS（idiopathic cytopenia of undetermined
    　　　　　　　　　significance）　
    　〔Pitfall〕　鉄芽球性貧血　
    　骨髄異形成症候群 <小児　>
    　赤芽球癆　
    　〔Mini Lecture〕　輸血後鉄過剰症

    第4章　続発性貧血
    　anemia of chronic disease (ACD)　
    　薬剤性貧血　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 造血必須物質の欠乏による貧血

P.18 掲載の参考文献
1) Andrews NC. Iron deficiency and related disorders. In : Greer JP, et al., eds. Wintrobe's Clinical Hematology. 12th ed. Philadelphia : Lippincott Williams & Wilkins ; 2008. pp.810-34.
 
2) 内田立身. 鉄欠乏性貧血の治療指針. 日本鉄バイオサイエンス学会治療指針作成委員会, 編. 鉄剤の適正使用による貧血治療指針. 改訂第2版. 札幌 ; 響文社 : 2009. pp.10-7.
 
P.22 掲載の参考文献
1) 藤村欣吾ほか, 厚生労働省難治性疾患克服研究事業 血液凝固異常症に関する調査研究班. 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨床血液 2012 ; 53 : 433-42.
 
2) Dufour C, et al. Helicobacter pylori gastric infection and sideropenic refractory anemia. J Pediatr Gastroenterol Nutr 1993 ; 17 : 225-7.
PubMed
3) Konno M, et al. Iron-deficiency anemia associated with Helicobacter pylori gastritis. J Pediatr Gastroenterol Nutr 2000 ; 31 : 52-6.
PubMed
4) Muhsen K, Cohen D. Helicobacter pylori infection and iron stores : a systematic review and meta-analysis. Helicobacter 2008 ; 13 : 323-40.
PubMed
5) Qu XH, et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol 2010 ; 16 : 886-96.
PubMed
6) Yuan W, et al. Iron deficiency anemia in Helicobacter pylori infection : meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010 ; 45 : 665-76.
PubMed
7) Husson MO, et al. Iron acquisition by Helicobacter pylori : importance of human lactoferrin. Infect Immun 1993 ; 61 : 2694-7.
PubMed
8) Dhaenens L, et al. Identification, characterization, and immunogenicity of the lactoferrin-binding protein from Helicobacter pylori. Infect Immun 1997 ; 65 : 514-8.
PubMed
9) Park SA, et al. Comparative proteomic analysis of Helicobacter pylori strains associated with iron deficiency anemia. Proteomics 2006 ; 6 : 1319-28.
PubMed
10) Lee JH, et al. The expression of iron-repressible outer membrane proteins in Helicobacter pylori and its association with iron deficiency anemia. Helicobacter 2009 ; 14 : 36-9.
PubMed
11) Yokota S, et al. Enhanced Fe ion-uptake activity in Helicobacter pylori strains isolated from patients with iron-deficiency anemia. Clin Infect Dis 2008 ; 46 : e31-3.
PubMed
12) Yokota S, et al. Positive relationship between a polymorphism in Helicobacter pylori neutrophil-activating protein A gene and iron-deficiency anemia. Helicobacter 2013 ; 18 : 112-6.
PubMed
P.28 掲載の参考文献
1) Ikuta K, et al. Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy. Clin Chim Acta 2011 ; 412 : 2261-6.
PubMed
2) 内田立身. 鉄欠乏性貧血の治療指針. 日本鉄バイオサイエンス学会治療指針作成委員会, 編. 鉄剤の適正使用による貧血治療指針. 改訂第2版. 札幌 : 響文社 ; 2009. pp.10-7.
 
3) Kohgo Y, et al. Serum transferrin receptor as a new index of erythropoiesis. Blood 1987 ; 70 : 1955-8.
PubMed
4) Skikne BS, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia : a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011 ; 86 : 923-7.
PubMed
5) Hosoki T, et al. Heterogeneous expressions of hepcidin isoforms in hepatoma-derived cells detected using simultaneous LC-MS/MS. Proteomics Clin Appl 2009 ; 3 : 1256-64.
 
6) Hershko C, et al. Non-specific serum iron in thalassaemia : an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978 ; 40 : 255-63.
PubMed
7) Sasaki K, et al. Improved quantification for non-transferrin-bound iron measurement using high-performance liquid chromatography by reducing iron contamination. Mol Med Rep 2011 ; 4 : 913-8.
PubMed
8) Alustiza Echeverria JM, et al. Quantification of iron concentration in the liver by MRI. Insights Imaging 2012 ; 3 : 173-80.
PubMed
9) Finberg KE, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008 ; 40 : 569-71.
PubMed
10) ヘモクロマトーシスの実態調査と診断基準作成班 (研究代表者 : 高後裕). 厚生労働科学研究費補助金難治性疾患克服研究事業. ヘモクロマトーシスの実態調査と診断基準作成 平成22年度研究報告書. 2011.
 
P.37 掲載の参考文献
1) Chanarin I. Historical review : a history of pernicious anaemia. Br J Haematol 2000 ; 111 : 407-15.
PubMed
2) Minot GR, Murphy WP. Treatment of pernicious anemia by a special diet. JAMA 1926 ; 87 : 470-6.
 
3) Kuzminski AM, et al. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998 ; 92 : 1191-8.
PubMed
Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med 2013 ; 368 : 149-60.
PubMed
Green R. Folate, cobalamin, and megaloblastic anemias. In : Kaushansky K, et al. Williams Hematology. 8th ed. McGraw-Hill Professional ; 2010. p.533.
 
Carmel R. Megaloblastic anemias : Disorders of impaired DNA synthesis. In : Greer JP, et al., eds. Wintrobe's Clinical Hematology. 12th ed. Lippincott Williams & Wilkins ; 2008. p.1143.
 
P.41 掲載の参考文献
1) Eide DJ. Zinc transporters and the cellular trafficking of zinc. Biochim Biophys Acta 2006 ; 1763 : 711-22.
PubMed
2) Nishiyama S, et al. Zinc status relates to hematological deficits in women endurance runners. J Am Coll Nutr 1996 ; 15 : 359-63.
PubMed
3) Sipahi T, et al. Plasma zinc levels in patients with iron-deficiency anemia. J Trop Pediatr 2001 ; 47 : 122-3.
PubMed
4) Nishiyama S, et al. Zinc status relates to hematological deficits in middle-aged women. J Am Coll Nutr 1998 ; 17 : 291-5.
PubMed
5) Iwasaki S, et al. Oral zinc supplementation reduces mean erythropoietin dose in EPOrequired hemodialysis patients. J Am Soc Nephrol 2001 ; 12 : 357A.
 
6) Wasa M, et al. Copper deficiency with pancytopenia during total parenteral nutrition. JPEN J Parenter Enteral Nutr 1994 ; 18 : 190-2.
PubMed
7) Gregg XT, et al. Copper deficiency masquerading as myelodysplastic syndrome. Blood 2002 ; 100 : 1493-5.
PubMed
8) Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc 2006 ; 81 : 1371-84.
PubMed
P.51 掲載の参考文献
1) 日本腎臓学会, 編. エビデンスに基づくCKD診療ガイドライン 2013. 東京 : 東京医学社 ; 2013.
 
2) Astor BC, et al. Association of kidney function with anemia : the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002 ; 162 : 1401-8.
PubMed
3) 日本透析医学会. 2008年版 慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 2008 ; 41 : 661-716.
 
4) Silverberg DS, et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin Nephrol 2002 ; 58 Suppl 1 : S37-45.
 
5) Gouva C, et al. Treating anemia early in renal failure patients slows the decline of renal function : a randomized controlled trial. Kidney Int 2004 ; 66 : 753-60.
PubMed
6) Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 2001 ; 38 : 415-25.
PubMed
7) Blumberg A, et al. Effect of altitude on erythropoiesis and oxygen affinity in anaemic patients on maintenance dialysis. Eur J Clin Invest 1973 ; 3 : 93-7.
PubMed
8) Levin A, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005 ; 46 : 799-811.
PubMed
9) Suzuki M, et al. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease. Int Heart J 2012 ; 53 : 238-43.
PubMed
10) Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 ; 355 : 2085-98.
PubMed
11) Shoji S, et al. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol 2013 ; 90 : 237-44.
 
P.57 掲載の参考文献
1) 厚生労働省. 日本人の食事摂取基準 2010年版. 東京 : 第一出版 ; 2010.
 
2) Monsen ER, et al. Estimation of available dietary iron. Am J Clin Nutr 1978 ; 31 : 134-41.
PubMed
3) Hunt JR. Dietary and physiological factors that affect the absorption and bioavailability of iron. Int J Vitam Nutr Res 2005 : 75 : 375-84.
PubMed
4) Brune M, et al. lron absorption : no intestinal adaptation to a high-phytate diet. Am J Clin Nutr 1989 : 49 : 542-5.
 
5) Hallberg L, Hulthen L. Prediction of dietary iron absorption : an algorithm for calculating absorption and bioavailability of dietary iron. Am J Clin Nutr 2000 ; 71 : 1147-60.
PubMed
6) 原田契一. 緑茶と鉄剤-緑茶の飲用は徐放性鉄剤の効果に影響を与えない. 日本薬剤師会雑誌 1986 ; 38 : 1145-8.
 

第2章 溶血性貧血

P.65 掲載の参考文献
1) 梶井英治ほか. 自己免疫性溶血性貧血 診療の参照ガイド (平成22年度改訂版). 小澤敬也, 編. 特発性造血障害疾患の診療の参照ガイド. 平成22年度改訂版. 2011. pp.141-76.
 
2) 大野良之. 溶血性貧血. 特定疾患治療研究事業未対象疾患の疫学像を把握するための調査研究班 平成11年度報告書. 2000. pp.31-88.
 
3) Perrotta S, et al. Hereditary spherocytosis. Lancet 2008 ; 372 : 1411-26.
PubMed
4) Koury MJ, Rhodes M. How to approach chronic anemia. Hematology Am Soc Hematol Educ Program 2012 ; 2012 : 183-90.
PubMed
5) George JN. How I treat patients with thrombotic thrombocytopenic purpura : 2010. Blood 2010 ; 116 : 4060-9.
 
P.74 掲載の参考文献
1) 梶井英治ほか. 自己免疫性溶血性貧血 診療の参照ガイド (平成22年度改訂版). 厚生労働科学研究費補助金難治性疾患克服研究事業 特発性造血障害に関する調査研究班. 特発性造血障害疾患の診療の参照ガイド. 平成22年度改訂版. 2011. pp.141-76. http://zoketsushogaihan.com/file/AIHA.pdf
 
2) Burton NM, Bruce LJ. Modelling the structure of the red cell membrane. Biochem Cell Biol 2011 ; 89 : 200-15.
PubMed
3) Lechner K, Jager U. How I treat autoimmune hemolytic anemias in adults. Blood 2010 ; 116 : 1831-8.
 
4) Penalver FJ, et al ; Multi-institutional Retrospective Study on the use of rituximab in refractory AIHA. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010 ; 89 : 1073-80.
PubMed
5) Barcellini W, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia : clinical efficacy and biologic studies. Blood 2012 ; 119 : 3691-7.
PubMed
6) Moyo VM, et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002 ; 100 : 704-6.
PubMed
7) Flores G, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia : results in 73 patients. Am J Hematol 1993 ; 44 : 237-42.
PubMed
8) Pignon JM, et al. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993 ; 83 : 343-5.
PubMed
9) Howard J, et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenic purpura. Br J Haematol 2002 ; 117 : 712-5.
PubMed
10) Kotb R, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias : a single center preliminary study. Eur J Haematol 2005 ; 75 : 60-4.
PubMed
11) Emilia G, et al. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol 1996 ; 93 : 341-4.
PubMed
12) Liu H, et al. The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome. Zhonghua Xue Ye Xue Za Zhi 2001 ; 22 : 581-3.
 
13) Rodon P, et al. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol 2003 ; 70 : 319-21.
PubMed
14) Karlsson C, et al. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007 ; 21 : 511-4.
 
15) Kaufman M, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 2009 ; 50 : 892-9.
 
16) Ahn YS, et al. Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets. JAMA 1983 ; 249 : 2189-94.
PubMed
17) Shvidel L, et al. Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia : rethinking old cures. Am J Hematol 2006 ; 81 : 423-5.
PubMed
18) Smith JW, et al ; AABB Hemapheresis Committee ; American Society for Apheresis. Therapeutic apheresis : a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003 ; 43 : 820-2.
PubMed
P.78 掲載の参考文献
1) Petz LD, Garratty G. Autoimmune hemolytic anemia with a negative direct antiglobulin test (DAT). In : Petz LD, Garratty G, eds. Immune Hemolytic Anemias. Philadelphia : Churchill Livingstone ; 2003. pp.319-34.
 
2) Kamesaki T, et al. Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombsnegative autoimmune hemolytic anemia. Am J Hematol 2009 ; 84 : 98-101.
PubMed
3) Kamesaki T, et al. Prevalence of Coombs-negative autoimmune hemolytic anemia associated with RBC-bound IgM and IgA. 臨床血液 2013 ; 54 : 1241.
 
4) Kamesaki T, et al. Characterization of direct antiglobulin test-negative autoimmune hemolytic anemia : a study of 154 cases. Am J Hematol 2013 ; 88 : 93-6.
PubMed
5) Wan SG, et al. Incipient Coombs' test negative autoimmune hemolytic anemia precedes non-Hodgkin's lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012 ; 20 : 97-9.
PubMed
6) 橋本亜香利ほか. Coombs陰性自己免疫性溶血性貧血を併発しリツキシマブが奏効した後天性無巨核球性血小板減少性紫斑病. 臨床血液 2013 ; 54 : 568-73.
 
P.83 掲載の参考文献
1) 小峰光博. 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する研究班総括研究報告 平成16年度報告書. 2005.
 
2) 小峰光博. 後天性溶血性貧血 免疫性溶血性貧血. 浅野茂隆ほか, 監. 三輪血液病学. 東京 : 文光堂 ; 2006. pp.1181-27.
 
3) 自己免疫性溶血性貧血 (AIHA) の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ (責任者 : 梶井英治). 自己免疫性溶血性貧血 診療の参照ガイド (平成22年度改訂版). 小澤敬也, 編. 特発性造血障害疾患の診療の参照ガイド. 平成22年度改訂版. 2011. pp.141-76.
 
4) 亀崎豊実, 梶井英治. 自己免疫性溶血性貧血. 『難治性貧血の診療ガイド』編集委員会, 編. 難治性貧血の診療ガイド-特発性造血障害の病態・診断・治療の最新動向. 東京 : 南江堂 ; 2011. pp.131-69.
 
5) 大野良之. 溶血性貧血. 特定疾患治療研究事業未対象疾患の疫学像を把握するための調査研究班 平成11年度報告書. 2000. pp.31-88.
 
6) Schreiber AD, et al. Low-titer cold-hemagglutinin disease. Mechanism of hemolysis and response to corticosteroids. N Engl J Med 1977 ; 296 : 1490-4.
PubMed
7) Berentsen S, et al. Rituximab for primary chronic cold agglutinin disease : a prospective study of 37 courses of therapy in 27 patients. Blood 2004 ; 103 : 2925-8.
PubMed
8) Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008 ; 141 : 149-69.
PubMed
P.86 掲載の参考文献
1) 小峰光博. 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する研究班総括研究報告 平成16年度報告書. 2005.
 
2) 小峰光博. 後天性溶血性貧血 免疫性溶血性貧血. 浅野茂隆ほか, 監. 三輪血液病学. 東京 : 文光堂 ; 2006. pp.1181-27.
 
3) 自己免疫性溶血性貧血 (AIHA) の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ (責任者 : 梶井英治). 自己免疫性溶血性貧血 診療の参照ガイド (平成22年度改訂版). 小澤敬也, 編. 特発性造血障害疾患の診療の参照ガイド. 平成22年度改訂版. 2011. pp.141-76.
 
4) 亀崎豊実, 梶井英治. 自己免疫性溶血性貧血. 『難治性貧血の診療ガイド』編集委員会, 編. 難治性貧血の診療ガイド-特発性造血障害の病態・診断・治療の最新動向. 東京 : 南江堂 ; 2011. pp.131-69.
 
5) 大野良之. 溶血性貧血. 特定疾患治療研究事業未対象疾患の疫学像を把握するための調査研究班 平成11年度報告書. 2000. pp.31-88.
 
P.98 掲載の参考文献
1) Parker C, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005 ; 106 : 3699-709.
PubMed
2) Rother RP, et al. The clinical sequelae of intravascular hemolysis and extracellular lasma hemoglobin : a novel mechanism of human disease. JAMA 2005 ; 293 : 1653-62.
 
3) 西村純一, 金倉譲. 発作性夜間ヘモグロビン尿症. 『難治性貧血の診療ガイド』編集委員会, 編. 難治性貧血の診療ガイド. 東京 : 南江堂 ; 2011. pp.93-130.
 
4) Rother RP, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007 ; 25 : 1256-64.
PubMed
5) Kanakura Y, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria : the AEGIS clinical trial. Int J Hematol 2011 ; 93 : 36-46.
PubMed
6) Kanakura Y, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH : AEGIS trial. Int J Hematol 2013 ; 98 : 406-16.
PubMed
7) Hillmen P, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007 ; 110 : 4123-8.
PubMed
8) Kelly RJ, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria : sustained efficacy and improved survival. Blood 2011 ; 117 : 6786-92.
PubMed
9) 西村純一ほか. C5遺伝子多型によるPNH 治療薬エクリズマブに対する不応性の解析. 補体シンポジウム講演集 2013 ; 50 : 44-5.
Medical*Online
10) Risitano AM, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009 ; 113 : 4094-100.
PubMed
発作性夜間ヘモグロビン尿症診療の参照ガイド 平成25年度改訂版. 2014. http://zoketsushogaihan.com/file/guideline_H25/4.pdf
 
P.105 掲載の参考文献
1) Yawata Y, et al. Hereditary red cell membrane disorders in Japan : their genotypic and phenotypic features in 1014 cases studied. Hematology 2001 ; 6 : 399-422.
PubMed
2) Yawata Y, et al. Characteristic features of the genotype and phenotype of hereditary spherocytosis in the Japanese population. Int J Hematol 2000 ; 71 : 118-35.
PubMed
3) Lux SE, Palek J. Disorders of the red cell membrane. In : Handin RI, et al., eds. Blood : Principles and Practice of Hematology. 2nd ed. Philadelphia : Lippincott Williams & Wilkins ; 2003. pp.1709-858.
 
4) Eber S, Lux SE. Hereditary spherocytosis-defects in proteins that connect the membrane skeleton to the lipid bilayer. Semin Hematol 2004 ; 41 : 118-41.
 
5) Yawata Y. Hereditary spherocytosis. In : Cell Membrane : The Red Blood Cell as a Model. Weinheim, Germany : Wiley-VCH ; 2003. p.40.
 
6) Bolton-Maggs PH, et al. Guidelines for the diagnosis and management of hereditary spherocytosis-2011 update. Br J Haematol 2012 ; 156 : 37-49.
PubMed
7) Casale M, Perrotta S. Splenectomy for hereditary spherocytosis : complete, partial or not at all? Expert Rev Hematol 2011 ; 4 : 627-35.
PubMed
8) Buesing KL, et al. Partial splenectomy for hereditary spherocytosis : a multi-institutional review. J Pediatr Surg 2011 ; 46 : 178-83.
PubMed
9) Schilling RF. Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis-a personal view. Br J Haematol 2009 ; 145 : 728-32.
PubMed
P.109 掲載の参考文献
1) Bianchi P, et al. Diagnostic power of laboratory tests for hereditary spherocytosis : a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica 2012 ; 97 : 516-23.
PubMed
2) 菅野仁. 2. 先天性溶血性貧血. VIII章 赤血球系疾患. 日本血液学会, 編. 血液専門医テキスト. 東京 : 南江堂 ; 2011. pp.154-8.
 
3) Valentine WN, et al. Lead poisoning : association with hemolytic anemia, basophilic stippling, erythrocyte pyrimidine 5′-nucleotidase deficiency, and intraerythrocytic accumulation of pyrimidines. J Clin Invest 1976 ; 58 : 926-32.
 
4) Miyazono Y, et al. Erythrocyte enzyme activities in cord blood of extremely low-birthweight infants. Am J Hematol 1999 ; 62 : 88-92.
PubMed
5) Mehta A, et al. Glucose-6-phosphate dehydrogenase deficiency. Baillieres Best Pract Res Clin Haematol 2000 ; 13 : 21-38.
PubMed
P.120 掲載の参考文献
1) Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th ed. Oxford, London : Blackwell Science ; 2001.
 
2) Steinberg MH, et al. Disorders of Hemoglobin : Genetics, Pathophysiology, and Clinical Management. 2nd ed. Cambridge University Press ; 2009.
 
3) United Kingdom Thalassemia Society. NUH Guidelines : Consensus view on choice or iron chelation therapy in transfusional iron overload for inherited anemias. http://www.emscg.nhs.uk/Library/NUHGuidelinesforironchelationtherapy.pdf
 
4) Pennell DJ, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica 2012 ; 97 : 842-8.
 
5) Lucarelli G, et al. Bone marrow transplantation in thalassemia. Semin Hematol 1995 ; 32 : 297-303.
PubMed
6) Lucarelli G, et al. Marrow transplantation for patients with thalassemia : results in class 3 patients. Blood 1996 ; 87 : 2082-8.
PubMed
7) Schrier SL, Angelucci E. New strategies in the treatment of the thalassemias. Annu Rev Med 2005 ; 56 : 157-71.
PubMed
8) Dong A, et al. Gene therapy for hemoglobinopathies : progress and challenges. Transl Res 2013 ; 161 : 293-306.
PubMed
9) Cavazzana-Calvo M, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010 ; 467 : 318-22.
 
10) Payen E, Leboulch P. Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies. Hematology Am Soc Hematol Educ Program 2012 ; 2012 : 276-83.
 
11) Takabayashi H, et al. Development of non-invasive fetal DNA diagnosis from maternal blood. Prenat Diagn 1995 ; 15 : 74-7.
PubMed
12) Cheung MC, et al. Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood. Nat Genet 1996 ; 14 : 264-8.
PubMed
13) Delhanty JD. Preimplantation diagnosis. Prenat Diagn 1994 ; 14 : 1217-27.
PubMed
14) Handyside AH, Delhanty JD. Preimplantation genetic diagnosis : strategies and surprises. Trends Genet 1997 ; 13 : 270-5.
PubMed
15) Kuliev A, et al. Preimplantation diagnosis of thalassemias. J Assist Reprod Genet 1998 ; 15 : 219-25.
PubMed
16) Kuliev A, et al. Birth of healthy children after preimplantation diagnosis of thalassemias. J Assist Reprod Genet 1999 ; 16 : 207-11.
PubMed
17) Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci 1998 ; 850 : 251-69.
PubMed
P.123 掲載の参考文献
1) Akiyama M, et al. Hemoglobin Hammersmith [β 42 (CD1) Phe → Ser] causing severe hemolytic anemia in a Japanese girl. Pediatr Blood Cancer 2006 ; 47 : 839-41.
 
2) Ohba Y, et al. Hemoglobin Mizuho or beta 68 (E 12) leucine leads to proline, a new unstable variant associated with severe hemolytic anemia. Hemoglobin 1977 ; 1 : 467-77.
PubMed
3) Yamada K, et al. Hemoglobin Tochigi disease, a new unstable hemoglobin hemolytic anemia found in a Japanese family. Nihon Ketsueki Gakkai Zasshi 1971 ; 34 : 484-97.
 
4) Nakatsuji T, et al. A new unstable hemoglobin, Hb Yokohama beta 31 (B13) Leu substituting for Pro, causing hemolytic anemia. Hemoglobin 1981 ; 5 : 667-78.
PubMed
5) Ohba Y, et al. Hemoglobin Saitama or beta 117 (G19) His leads to Pro, a new variant causing hemolytic disease. Hemoglobin 1983 ; 7 : 47-56.
 
6) Phyliky RL, Fairbanks VF. Thromboembolic complication of splenectomy in unstable hemoglobin disorders : Hb Olmsted, Hb Koln. Am J Hematol 1997 ; 55 : 53.
PubMed
7) Shinohara K, Hattori Y. Two patients in a family with unstable hemoglobin, Hb Hirosaki : anemia was ameliorated but hemolysis persists after splenectomy. Int J Hematol 2006 ; 84 : 186-7.
 
8) Honig GR, et al. Hemoglobin Evanston (α14 Trp → Arg). An unstable α-chain variant expressed as α-thalassemia. J Clin Invest 1984 ; 73 : 1740-9.
 

第3章 骨髄不全とその周辺疾患

P.133 掲載の参考文献
1) Sugimori N, et al. Aberrant increase in the immature platelet fraction in patients with myelodysplastic syndrome : a marker of karyotypic abnormalities associated with poor prognosis. Eur J Haematol 2009 ; 82 : 54-60.
PubMed
2) Sugimori C, et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositolanchored protein among patients with bone marrow failure. Br J Haematol 2009 ; 147 : 102-12.
PubMed
3) Sugimori C, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006 ; 107 : 1308-14.
PubMed
4) Katagiri T, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 2011 ; 118 : 6601-9.
PubMed
5) Feng X, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2011 ; 96 : 602-6.
PubMed
6) Seiki Y, et al. Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome : a reliable marker for a benign subset of bone marrow failure. Haematologica 2013 ; 98 : 901-7.
PubMed
7) Yamazaki H, Nakao S. Border between aplastic anemia and myelodysplastic syndrome. Int J Hematol 2013 ; 97 : 558-63.
PubMed
P.141 掲載の参考文献
1) Vardiman JW, et al. Introduction and overview of the classification of the myeloid neoplasms. In : Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press ; 2008. pp.17-30.
 
2) Mufti GJ, et al. Diagnosis and classification of myelodysplastic syndrome : International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008 ; 93 : 1712-7.
 
3) Kuriyama K, et al. Diagnostic significance of detecting pseudo-Pelger-Huet anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol 1986 ; 63 : 665-9.
PubMed
4) Bain BJ. Leukaemia Diagnosis. Oxford : Blackwell Science ; 1999. pp.113-42.
 
5) Brunning RD, et al : Myelodysplastic syndromes, overview. In : Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press ; 2008. pp.88-93.
 
6) Valent P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes : consensus statements and report from a working conference. Leuk Res 2007 ; 31 : 727-36.
PubMed
7) Vardiman JW, et al. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002 ; 100 : 2292-302.
PubMed
8) 松田晃ほか. 不応性貧血 (骨髄異形成症候群) の形態学的異形成に基づく診断確度区分. 朝長万左男, 松田晃, 編. 不応性貧血 (骨髄異形成症候群) の形態学的異形成に基づく診断確度区分と形態診断アトラス. 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究 (平成19年度). 2008. pp.1-15.
 
9) Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012 ; 120 : 2454-65.
PubMed
10) Germing U, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Dusseldorf Registry on myelodysplastic syndromes. Leuk Res 2012 ; 36 : 727-34.
PubMed
P.149 掲載の参考文献
1) 伊藤雅文. 病理. 最新医学別冊 新しい診断と治療のABC 72. 小澤敬也, 編. 再生不良性貧血. 大阪 : 最新医学社 ; 2011. pp.31-8.
 
2) 小原明. 日本における小児再生不良性貧血など造血障害性疾患の現状-日本小児血液学会再生不良性貧血委員会疫学調査 1988-2005年. 日小血会誌 2008 ; 22 : 53-62.
 
3) Baumann I, et al. Childhood myelodysplastic syndrome. In : Swerdlow SH, et al., eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC press ; 2008. pp.104-7.
 
4) Bohm J. Gelatinous transformation of the bone marrow : the spectrum of underlying diseases. Am J Surg Pathol 2000 ; 24 : 56-65.
 
5) 濱麻人, 伊藤雅文. MDS 骨髄病理診断の標準化. 病理と臨床 2012 ; 30 : 832-9.
Medical*Online
6) 伊藤雅文. 薬剤性造血器障害-病理. 病理と臨床 2009 ; 27 : 733-9.
Medical*Online
7) Choi JW, et al. Significance of fetal hemoglobin-containing erythroblasts (F blasts) and the F blast/F cell ratio in myelodysplastic syndromes. Leukemia 2002 ; 16 : 1478-83.
 
8) Choi JW, et al. F blast production correlates strongly with upregulation of inducible nitric oxide synthase in myelodysplastic syndromes. Ann Hematol 2002 ; 81 : 548-50.
PubMed
9) J adersten M, et al. TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression. J Clin Oncol 2011 ; 29 : 1971-9.
 
P.156 掲載の参考文献
1) Brunning R, et al. Myelodysplastic syndromes/neoplasms, overview. In : Swerdlow S, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press ; 2008. pp.88-93.
 
2) Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012 ; 120 : 2454-65.
PubMed
3) Ishiyama K, et al. Aplastic anaemia with 13q- : a benign subset of bone marrow failure responsive to immunosuppressive therapy. Br J Haematol 2002 ; 117 : 747-50.
PubMed
4) Geary CG, et al. Abnormal cytogenetic clones in patients with aplastic anaemia : response to immunosuppressive therapy. Br J Haematol 1999 ; 104 : 271-4.
PubMed
5) Tiu RV, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011 ; 117 : 4552-60.
PubMed
6) Gangat N, et al. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. Am J Hematol 2013 ; 88 : 690-3.
PubMed
7) Valcarcel D, et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol 2013 ; 31 : 916-22.
 
8) Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011 ; 364 : 2496-506.
PubMed
9) Bejar R, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012 ; 30 : 3376-82.
PubMed
10) Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011 ; 478 : 64-9.
PubMed
P.161 掲載の参考文献
1) 緒方清行. 疫学. 最新医学別冊 新しい診断と治療のABC 19. 吉田彌太郎, 編. 骨髄異形成症候群. 大阪 : 最新医学社 ; 2004. pp.15-22.
 
2) Hamblin T. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk Res 1992 ; 16 : 3.
PubMed
3) Ogata K, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002 ; 100 : 3887-96.
PubMed
4) Ogata K, et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006 ; 108 : 1037-44.
PubMed
5) Ogata K, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes : a prospective validation study. Haematologica 2009 ; 94 : 1066-74.
PubMed
6) Mathis S, et al. Flow cytometric detection of dyserythropoiesis : a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia 2013 ; 27 : 1981-7.
PubMed
7) van de Loosdrecht AA, et al. Standardization of flow cytometry in myelodysplastic syndromes : report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009 ; 94 : 1124-34.
PubMed
8) Westers TM, et al. Standardization of flow cytometry in myelodysplastic syndromes : a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012 ; 26 : 1730-41.
 
9) 緒方清行. MDSのフローサイトメトリー. 松田晃, 編. 骨髄異形成症候群 (MDS) 診療up-to-date. 東京 : 中外医学社 ; 2011. pp.49-56.
 
P.165 掲載の参考文献
1) Kusumoto S, et al. Bone marrow patterns in patients with aplastic anaemia and myelodysplastic syndrome : observations with magnetic resonance imaging. Eur J Haematol 1997 ; 59 : 155-61.
PubMed
2) Matsuura H, et al. Quantitative analysis of magnetic resonance imaging susceptibility artifacts caused by neurosurgical biomaterials : comparison of 0.5, 1.5, and 3.0 Tesla magnetic fields. Neurol Med Chir 2005 ; 45 : 395-8.
 
3) Vogler JB 3rd, Murphy WA. Bone marrow imaging. Radiology 1988 ; 168 : 679-93.
PubMed
4) Vande Berg BC, et al. Magnetic resonance imaging of normal bone marrow. Eur Radiol 1998 ; 8 : 1327-34.
PubMed
5) 田中修ほか. 脊椎の骨髄疾患. 画像診断 2012 ; 32 : 641-53.
 
6) 小澤栄人ほか. 骨髄造血組織評価. 臨床検査 2002 ; 46 : 1319-23.
 
Pansini V, et al. 3 tesla 1H MR spectroscopy of hip bone marrow in a healthy population, assessment of normal fat content values and influence of age and sex. J Magn Res on Imaging 2014 ; 39 : 369-76.
 
P.176 掲載の参考文献
1) Bennett JM, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982 ; 51 : 189-99.
PubMed
2) Brunning RD, et al. Myelodysplastic syndromes : Introduction. In : Jaffe ES, et al., eds. World Health Organization Classification of Tumours : Pathology and Genetics of Tumour of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press ; 2001. pp.63-7.
 
3) Brunning R, et al. Myelodysplastic syndromes/neoplasms, overview. In : Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press ; 2008. pp.88-93.
 
4) Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 ; 89 : 2079-88.
PubMed
5) Greenberg PL, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood 2012 ; 120 : 2454-65.
PubMed
6) Malcovati L, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007 ; 25 : 3503-10.
PubMed
7) Malcovati L, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011 : 96 : 1433-40.
PubMed
8) Hosokawa K, et al. Favorable outcome of patients who have 13q deletion : a suggestion for revision of the WHO 'MDS-U' designation. Haematologica 2012 ; 97 : 1845-9.
PubMed
9) Schanz J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012 ; 30 : 820-9.
PubMed
10) Kantarjian H, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008 ; 113 : 1351-61.
 
11) Schanz J, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011 ; 29 : 1963-70.
PubMed
12) Matsuda A, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005 ; 106 : 2633-40.
PubMed
13) Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011 ; 364 : 2496-506.
PubMed
14) Makishima H, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013 ; 45 : 942-6.
PubMed
Voso MT, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System : validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 2013 ; 31 : 2671-7.
PubMed
P.191 掲載の参考文献
1) 朝長万左男, 松田晃, 編. 不応性貧血 (骨髄異形成症候群) の形態学的異形成に基づく診断確度区分と形態診断アトラス. 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究 (平成19年度). 2008.
 
2) Hosokawa K, et al. Favorable outcome of patients who have 13q deletion : a suggestion for revision of the WHO 'MDS-U' designation. Haematologica 2012 ; 97 : 1845-9.
PubMed
3) Sugimori C, et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositolanchored protein among patients with bone marrow failure. Br J Haematol 2009 ; 147 : 102-12.
PubMed
4) Sugimori C, et al. Minor population of CD55- CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006 ; 107 : 1308-14.
PubMed
5) Kulagin A, et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression : results of two-centre prospective study. Br J Haematol 2014 ; 164 : 546-54.
PubMed
6) Wang H, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002 ; 100 : 3897-902.
PubMed
7) Seiki Y, et al. Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome : a reliable marker for a benign subset of bone marrow failure. Haematologica 2013 ; 98 : 901-7.
PubMed
8) Sugimori N, et al. Aberrant increase in the immature platelet fraction in patients with myelodysplastic syndrome : a marker of karyotypic abnormalities associated with poor prognosis. Eur J Haematol 2009 ; 82 : 54-60.
PubMed
9) 中尾眞二ほか. 再生不良性貧血診療の参照ガイド (2014年改訂). 黒川峰夫, 編. 特発性造血障害疾患の診療の参照ガイド. 平成25年度改訂版. 2014. http://zoketsushogaihan.com/file/guideline_H25/1.pdf
 
10) Olnes MJ, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012 ; 367 : 11-9.
PubMed
P.195 掲載の参考文献
1) Aalto SM, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007 ; 45 : 1305-9.
 
2) Wagner HJ, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004 ; 103 : 3979-81.
PubMed
3) van Esser JW, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001 ; 98 : 972-8.
PubMed
4) Scheinberg P, et al. Distinct EBV and CMV reactivation patterns following antibodybased immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007 ; 109 : 3219-24.
PubMed
5) Ohata K, et al. An Epstein-Barr virus-associated leukemic lymphoma in a patient treated with rabbit antithymocyte globulin and cyclosporine for hepatitis-associated aplastic anemia. Acta Haematol 2012 ; 127 : 96-9.
 
6) Peres E, et al. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens. J Clin Microbiol 2005 ; 43 : 3540-3.
PubMed
7) Atta EH, et al. Comparison between horse and rabbit antithymocyte globulin as firstline treatment for patients with severe aplastic anemia : a single-center retrospective study. Ann Hematol 2010 ; 89 : 851-9.
PubMed
8) Stevens SJ, et al. Toward standardization of Epstein-Barr virus DNA load monitoring : unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001 ; 39 : 1211-6.
PubMed
P.206 掲載の参考文献
1) Kamio T, et al. Relapse of aplastic anemia in children after immunosuppressive therapy : a report from the Japan Childhood Aplastic Anemia Study Group. Haematologica 2011 ; 96 : 814-9.
 
2) Fuhrer M, et al. Immunosuppressive therapy for aplastic anemia in children : a more severe disease predicts better survival. Blood 2005 ; 106 : 2102-4.
PubMed
3) Fuhrer M. Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia. Bone Marrow Transplant 2008 ; 42 Suppl 2 : S97-100.
 
4) Saracco P, et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia : a multicentre retrospective study with long-term observation follow-up. Br J Haematol 2008 ; 140 : 197-205.
PubMed
5) Scheinberg P, et al. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr 2008 ; 153 : 814-9.
PubMed
6) 日本造血細胞移植学会データセンター. 日本造血細胞移植学会平成24年度全国調査報告書. 2013.
 
7) Kennedy-Nasser AA, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006 ; 12 : 1277-84.
PubMed
8) Samarasinghe S, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy : a United Kingdom multicentre retrospective experience. Br J Haematol 2012 ; 157 : 339-46.
PubMed
9) Bacigalupo A, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia : a retrospective study from the EBMT-SAA Working Party. Haematologica 2010 ; 95 : 976-82.
 
10) Hama A, et al. Risk Factors for Donor-Type Aplasia After Bone Marrow Transplant in Children with Acquired Bone Marrow Failure Syndrome. ASH Annual Meeting Abstracts 2012 ; 120.
 
11) Passweg JR, Marsh JC. Aplastic anemia : first-line treatment by immunosuppression and sibling marrow transplantation. Hematology Am Soc Hematol Educ Program 2010 ; 2010 : 36-42.
PubMed
12) Yoshimi A, et al. Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children. Blood 2013 ; 121 : 860-1.
PubMed
13) Scheinberg P, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011 ; 365 : 430-8.
PubMed
14) Takahashi Y, et al. Rabbit antithymocyte globulin and cyclosporine as first-line therapy for children with acquired aplastic anemia. Blood 2013 ; 121 : 862-3.
PubMed
15) Chen C, et al. Rabbit-antithymocyte globulin combined with cyclosporin A as a first-line therapy : improved, effective, and safe for children with acquired severe aplastic anemia. J Cancer Res Clin Oncol 2012 ; 138 : 1105-11.
PubMed
16) Huang IA, et al. Single-Center Experience : immunosuppressive therapy as frontline treatment for 33 children with acquired severe aplastic anemia. Pediatr Hematol Oncol 2009 ; 26 : 487-95.
PubMed
17) Li X, et al. Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia : a single-center experience. PLoS One 2013 ; 8 : e56648.
PubMed
18) Yagasaki H, et al. Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood 2011 ; 118 : 3186-90.
PubMed
19) Scheinberg P, et al. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2012 ; 119 : 345-54.
PubMed
20) Gomez-Almaguer D, et al. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann Hematol 2010 ; 89 : 299-303.
PubMed
21) Brodsky RA, et al. High-dose cyclophosphamide for severe aplastic anemia : long-term follow-up. Blood 2010 ; 115 : 2136-41.
PubMed
22) Audino AN, et al. High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children. Pediatr Blood Cancer 2010 ; 54 : 269-72.
PubMed
23) Alsultan A, et al. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. Pediatr Blood Cancer 2009 ; 52 : 626-30.
PubMed
24) Jaime-Perez JC, et al. Danazol as first-line therapy for aplastic anemia. Ann Hematol 2011 ; 90 : 523-7.
PubMed
25) Zhang F, et al. High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia. Exp Hematol 2013 ; 41 : 328-34.
PubMed
26) Socie G, et al. Granulocyte-stimulating factor and severe aplastic anemia : a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007 ; 109 : 2794-6.
 
Pulsipher MA, et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters : conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant 2011 ; 17 : 291-9.
 
Samarasinghe S, Webb DK. How I manage aplastic anaemia in children. Br J Haematol 2012 ; 157 : 26-40.
 
Scheinberg P. Aplastic anemia : therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program 2012 : 2012 : 292-300.
PubMed
P.212 掲載の参考文献
1) 山下孝之ほか. Fanconi貧血の分子病態-最近の進歩. 臨床血液 2009 ; 50 : 538-46.
 
2) Sasaki MS, Tonomura A. A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 1973 ; 33 : 1829-36.
PubMed
3) Locatelli F, et al. The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen : a report from the Italian pediatric group. Haematologica 2007 ; 92 : 1381-8.
 
4) Yabe M, et al. Matched sibling donor stem cel transplantation for Fanconi anemia patients with T-cell somatic mosaicism. Pediatr Transplant 2012 ; 16 : 340-5.
 
5) Yabe H, et al. Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia. Br J Haematol 2006 ; 134 : 208-12.
PubMed
6) Kutler DI, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003 ; 101 : 1249-56.
PubMed
7) Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010 ; 24 : 101-22.
PubMed
8) Mehta PA, et al. Chemotherapy for myeloid malignancy in children with Fanconi anemia. Pediatr Blood Cancer 2007 ; 48 : 668-72.
PubMed
P.213 掲載の参考文献
1) 矢部みはる. Fanconi貧血の診断と治療. 日児誌 2012 ; 116 : 1205-12.
 
P.219 掲載の参考文献
1) Kirwan M, Dokal I. Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys Acta 2009 ; 1792 : 371-9.
PubMed
2) Mitchell JR, et al. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999 ; 402 : 551-5.
 
3) Gramatges MM, Bertuch AA. Short telomeres : from dyskeratosis congenita to sporadic aplastic anemia and malignancy. Transl Res 2013 162 : 353-63.
PubMed
4) Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000 ; 110 : 768-79.
PubMed
5) Walne AJ, Dokal I. Advances in the understanding of dyskeratosis congenita. Br J Haematol 2009 ; 145 : 164-72.
PubMed
6) Vulliamy TJ, et al. Mutations in dyskeratosis congenita : their impact on telomere length and the diversity of clinical presentation. Blood 2006 ; 107 : 2680-5.
PubMed
7) Heiss NS, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998 ; 19 : 32-8.
 
8) Vulliamy T, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001 ; 413 : 432-5.
PubMed
9) Armanios M, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 2005 ; 102 : 15960-4.
PubMed
10) Marrone A, et al. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood 2007 ; 110 : 4198-205.
PubMed
11) Walne AJ, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 2007 ; 16 : 1619-29.
PubMed
12) Vulliamy T, et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci U S A 2008 ; 105 : 8073-8.
PubMed
13) Vulliamy TJ, et al. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2005 ; 34 : 257-63.
PubMed
14) Savage SA, et al. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008 ; 82 : 501-9.
PubMed
15) Zhong F, et al. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes Dev 2011 ; 25 : 11-6.
PubMed
16) Venteicher AS, et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 2009 ; 323 : 644-8.
PubMed
17) Ballew BJ, et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita. Hum Genet 2013 ; 132 : 473-80.
PubMed
18) Calado RT, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009 ; 114 : 2236-43.
PubMed
19) Alter BP, et al. Treatment of dyskeratosis congenita with granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 1997 ; 97 : 309-11.
PubMed
20) de la Fuente J, Dokal I. Dyskeratosis congenita : advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 2007 ; 11 : 584-94.
PubMed
21) Dietz AC, et al. Disease-specific hematopoietic cell transplantation : nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2011 ; 46 : 98-104.
PubMed
22) Nishio N, et al. Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita. Pediatr Transplant 2011 : 15 : 161-6.
PubMed
P.229 掲載の参考文献
1) Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011 ; 478 : 64-9.
PubMed
2) Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 ; 89 : 2079-88.
PubMed
3) Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012 ; 120 : 2454-65.
PubMed
4) List A, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 ; 355 : 1456-65.
PubMed
5) Ishikawa T, et al. A Prospective Study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome : presence of CD55 (-) CD59 (-) blood cells predicts platelet response. Int J Hematol 2007 ; 86 : 150-7.
PubMed
6) Fenaux P, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, openlabel, phase III study. Lancet Oncol 2009 ; 10 : 223-32.
PubMed
7) Lim Z, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010 ; 28 : 405-11.
 
P.232 掲載の参考文献
1) Tasaka T, et al. Myelodysplastic syndrome with chromosome 5 abnormalities : a nationwide survey in Japan. Leukemia 2008 ; 22 : 1874-81.
PubMed
2) Boultwood J, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002 ; 99 : 4638-41.
PubMed
3) Ebert BL, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008 ; 451 : 335-9.
PubMed
4) Barlow JL, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010 ; 16 : 59-66.
 
5) Starczynowski DT, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010 ; 16 : 49-58.
PubMed
6) List A, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 ; 355 : 1456-65.
PubMed
7) Ades L, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion : results of a phase 2 study. Blood 2009 ; 113 : 3947-52.
 
8) Leitch HA, et al. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes : a clinical practice guideline. Crit Rev Oncol Hematol 2013 ; 85 : 162-92.
PubMed
9) Gohring G, et al. Patients with del (5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2010 ; 89 : 365-74.
PubMed
10) Kuendgen A, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del (5q) : a comparative analysis. Leukemia 2013 ; 27 : 1072-9.
 
P.236 掲載の参考文献
1) Valent P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes : consensus statements and report from a working conference. Leuk Res 2007 ; 31 : 727-36.
PubMed
2) 松田晃ほか. 不応性貧血 (骨髄異形成症候群) の形態学的診断基準 (案). 特発性造血障害に関する調査研究班 平成18年度総括-分担報告書. 2007. pp.75-6.
 
3) Hanson C, et al. Is idiopathic cytopenia of undetermined significance (ICUS) a valid clinical concept? A longitudial clinicopathological study. Leuk Res 2009 ; 33 : S109-S11. (第10回国際MDS シンポジウム抄録)
 
4) Schroeder T, et al. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS) : HUMURA unravels clonality in a subgroup of patients. Ann Oncol 2010 ; 21 : 2267-71.
 
5) Ando K, et al. Idiopathic neutropenia with fewer than 5% dysplasia may be a distinct entity of idiopathic cytopenia of undetermined significance. Ann Hematol 2010 ; 89 : 733-5.
PubMed
6) Ando K, et al. PNH-phenotype cells in patients with idiopathic cytopenia of undetermined significance (ICUS) with megakaryocytic hypoplasia and thrombocytopenia. Br J Haematol 2010 ; 150 : 705-7.
PubMed
P.239 掲載の参考文献
1) Ohba R, et al. Clinical and genetic characteristics of congenital sideroblastic anemia : comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). Ann Hematol 2013 ; 92 : 1-9.
PubMed
2) Bergmann AK, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia : evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 2010 ; 54 : 273-8.
PubMed
3) Harigae H, Furuyama K. Hereditary sideroblastic anemia : pathophysiology and gene mutations. Int J Hematol 2010 ; 92 : 425-31.
PubMed
4) Brunning RD, et al. Myelodysplastic syndromes/neoplasms, overview. In : Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC Press ; 2008. pp.88-93.
 
5) Ponka P, et al. Hereditary and aquired sideroblastic anemias. In : Kaushansky K, et al., eds. Williams Hematology. 8th ed. McGraw-Hill Professional Pub ; 2010. pp.865-81.
 
6) Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011 ; 478 : 64-9.
PubMed
7) 新津洋司郎ほか. 鉄芽球性貧血. 浅野茂隆ほか, 監. 三輪血液病学. 第3版. 東京 : 文光堂 ; 2006. pp.1018-23.
 
8) Malcovati L, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007 ; 25 : 3503-10.
PubMed
9) NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. Version 2. 2011.
 
10) Silverman LR, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome : a study of the cancer and leukemia group B. J Clin Oncol 2002 ; 20 : 2429-40.
 
P.248 掲載の参考文献
1) Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia : molecular classification and treatment options. Br J Haematol 2008 ; 140 : 610-24.
PubMed
2) Hasle H, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003 ; 17 : 277-82.
 
3) 日本小児血液学会MDS委員会, 編. 小児MDS図譜 2002. CD版. 2002.
 
4) Baumann I, et al. Childhood myelodysplastic syndrome. In : Swerdlow SH, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC Press ; 2008. pp.104-7.
 
5) Kardos G, et al. Refractory anemia in childhood : a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003 ; 102 : 1997-2003.
PubMed
6) Gohring G, et al. Complex karyotype newly defined : the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood 2010 ; 116 : 3766-9.
PubMed
7) Strahm B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children : results of the EWOG-MDS98 study. Leukemia 2011 ; 25 : 455-62.
PubMed
8) Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000 ; 110 : 512-24.
PubMed
9) 伊藤悦朗. 急性巨核球性白血病とGATA1遺伝子変異. 臨床血液 2006 ; 47 : 1415-22.
 
P.255 掲載の参考文献
1) Dessypris E, Lipton J. Red cell aplasia. In : Green JP, et al., eds. Wintrobe's Clinical Hematology. 12th ed. Philadelphia and London : Lippincott Williams & Wilkins ; 2008. pp.1196-211.
 
2) 澤田賢一ほか. 赤芽球癆診療の参照ガイド. 臨床血液 2006 ; 47 : 316-30.
 
3) 澤田賢一, 廣川誠. 赤芽球癆. 難治性貧血の診療ガイド編集委員会, 編. 難治性貧血の診療ガイド-特発性造血障害の病態・診断・治療の最新動向. 東京 : 南江堂 ; 2011. pp.31-52.
 
4) Konno Y, et al. Mutations in the ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia. Haematologica 2010 ; 95 : 1293-9.
PubMed
5) Sawada K, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 2007 ; 92:1021-8.
 
6) Sawada K, et al. Acquired pure red cell aplasia : updated review of treatment. Br J Haematol 2008 ; 142 : 505-14.
PubMed
7) Hirokawa M, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia : a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 2008 ; 93 : 27-33.
 
8) Fujishima N, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia : a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008 ; 93 : 1555-9.
 
9) Hirokawa M, et al. Acquired pure red cell aplasia associated with malignant lymphomas : a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Am J Hematol 2009 ; 84 : 144-8.
 
10) Hirokawa M, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant 2013 ; 19 : 1026-32.
 
P.262 掲載の参考文献
1) Takatoku M, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007 ; 78 : 487-94.
PubMed
2) Malcovati L, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria : a basis for clinical decision making. J Clin Oncol 2005 ; 23 : 7594-603.
PubMed
3) Suzuki T, et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol 2008 ; 88 : 30-5.
PubMed
4) 小澤敬也ほか. 輸血後鉄過剰症の診療ガイド. 厚生労働科学研究費補助金難治性疾患克服研究事業 特発性造血障害に関する調査研究 (平成20年度). 2008. http://www.jichi.ac.jp/zoketsushogaihan/tetsufinal.pdf
 
5) Vichinsky E. Clinical application of deferasirox : practical patient management. Am J Hematol 2008 ; 83 : 398-402.
PubMed
6) Rose C, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010 ; 34 : 864-70.
PubMed
7) Kikuchi S, et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic Biol Med 2012 ; 53 : 643-8.
PubMed

第4章 続発性貧血

P.272 掲載の参考文献
1) Punnonen K, et al. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997 ; 89 : 1052-7.
PubMed
Ganz T. Anemia of chronic disease. In : Kaushansky K, et al., eds. Williams Hematology. 8th ed. New York : McGraw-Hill ; 2010. p.503.
 
Means RT Jr. Anemias secondary to chronic disease and systemic disorders. In : Greer JP, et al., eds. Wintrobe's Clinical Hematology. 12th ed. Philadelphia : Lippincott Williams & Wilkins ; 2009. pp.1221-38.
 
Schrier SL, Camaschella C. Anemia of chronic disease (anemia of chronic inflammation). In : Landaw SA, eds. UpToDate. (http://www.uptodate.com/)
 
澤田賢一ほか. 特集/鉄代謝の臨床-鉄欠乏と鉄過剰. 日内会誌 2010 ; 99 (6).
 
Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011 ; 117 : 4425-33.
PubMed
Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012 ; 338 : 768-72.
PubMed
小松則夫. エリスロポエチンを用いた貧血の治療. 内科 2013 ; 112 : 301-4.
 
Rizzo JD, et al. American Society of Clinical Oncology ; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010 ; 28 : 4996-5010.
 
P.280 掲載の参考文献
1) 厚生労働省. 重篤副作用疾患別対応マニュアル. 薬剤性貧血. 2007. pp.8-29.
 
2) Shander A, et al. Drug-induced anemia and other red cell disorders : a guide in the age of polypharmacy. Curr Clin Pharmacol 2011 ; 6 : 295-303.
PubMed
3) 厚生労働科学研究費補助金 難治性疾患克服研究事業 特発性造血障害に関する調査研究班. 小澤敬也, 編. 特発性造血障害疾患の診療の参照ガイド. 平成22年度改訂版. 2010.
 
4) Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2009 ; 73-9.
PubMed
5) 森重聡ほか. 薬剤起因性貧血. 別冊日本臨牀 新領域別症候群シリーズ 26. 血液症候群 I. 第2版. 大阪 : 日本臨牀社 ; 2013. pp.408-11.
 
6) Dessypris EN, Lipton JM. Red cell aplasia. In : Greer JP, et al., eds. Wintrobe's Clinical Hematology. 11th ed. Philadelphia : Lippincott Williams & Wilkins ; 2004. pp.1421-7.
 
7) Macdougall IC, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009 ; 361 : 1848-55.
PubMed
8) Marsh JC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009 ; 147 : 43-70.
PubMed
9) 中尾眞二. 薬剤性再生不良性貧血. 別冊日本臨牀 新領域別症候群シリーズ 26. 血液症候群 I. 第2版. 大阪 : 日本臨牀社 ; 2013. pp.33-6.
 

書評

最近チェックした商品履歴

Loading...